Northpond Ventures GP, LLC's Form 4 filing
Vigil Neuroscience, Inc.VIGL · filed Jan 11, 2022
- Accession no.
- 0000899243-22-001631
- Filed
- Jan 11, 2022, 8:18 PM ET
- Trade date
- Jan 11, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $4.97M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Northpond Ventures GP, LLCCIK 0001867470 | 10% Owner |
| Northpond Ventures, LPCIK 0001867472 | 10% Owner |
| Rubin Michael P.CIK 0001867627 | 10% Owner |
| Northpond Ventures II GP, LLCCIK 0001869114 | 10% Owner |
| Northpond Ventures II, LPCIK 0001869128 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2022 | Common Stock | CConversionAcquired | +2,831,520 | –F1 | – | 2,831,520 | Indirect | Duplicate filing |
| Jan 11, 2022 | Common Stock | CConversionAcquired | +1,027,978 | –F1 | – | 1,027,978 | Indirect | Duplicate filing |
| Jan 11, 2022 | Common Stock | PPurchaseAcquired | +355,000 | $14.00 | +$4,970,000 | 1,382,978 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the "Issuer"), each share of Series A Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the "Series B Preferred Stock") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.